AB0554 SLEEP QUALITY IN PATIENTS WITH PSORIATIC ARTHRITIS

Background: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease. It has heterogeneous clinical presentation with main features being joint swelling and pain, skin nail psoriasis, enthesitis, dactylitis. Self-reported outcomes such as quality of sleep fatigue are often neglected topics although having great impact on patients’ everyday lives. Objectives: The primary objective was to analyze the prevalence PsA patients suffering from poor sleep, defined by Pittsburgh Sleep Quality Index (PSQI) score ≥ 5, study association between good or sleeper clinical- patient-reported outcomes. Secondary, effects after initiation treatment. Methods: Patient characteristics, disease activity self-reported were obtained PIPA cohort. To evaluate objective, cross-sectional analysis conducted including PSQI at baseline corresponding data. Patients divided into two groups, sleepers (Table 1). Data treatment (baseline) 4 months follow-up included when assessing effect Transition depicted chi-squared test. A crosstab performed whether they had widespread pain investigate possible link, additionally Mann-Whitney U Results: From January 2018-November 2020 total 109 included. 66.1% whereas remaining 33.9% deemed sleepers. There no statistically significant difference in patient demographics comparing baseline. Visual Analogue Scale (VAS) VAS global, Health Assessment Questionnaire (HAQ) Disease Activity Score (DAS28-CRP), scoring higher. 57 complete data follow-up. At 71.9% them classified (Figure test presented transition 47.4% now While 27 became sleepers, 13 (p 0.001). exposed 75 without (mean 7.13±3.79) 31 9.52±4.93). Baseline 0.018). Conclusion: Overall, have higher levels terms activity. amount increased, but there negative going This could indicate that more factors important for e.g. sociopsychological aspects like anxiety, depression, ability work. Table 1. characteristics Total n = Good ≤ 5 37 Poor > 72 p Female, (%) 65 (59.4%) 19 (51.4%) 46 (63.9%) 0.206 Age, yrs 53.9 (45.4-62.25) 60.4 (45.5-65.2) 51.5 (44.7-59.95) 0.144 duration, 3.86 (1.0-11.0) 4.5 (1.04-11.06) 34 2.91 (1.0-10.75) 68 0.352 csDMARD, 71 (65.1%) 26 (70.2%) 45 (62.5%) 0.420 bDMARD, 70 (64.2%) 24 (64.8%) 0.920 assessment 0-100 mm 50.0 (21.0-74.5) 27.0 (9.0-60.5) 63.5 (32.25-78.0) <0.001 global 61.0 (27.5-78.5) 35.0 (17.5-59.0) 69.5 (50.0-85.75) PsAID 6.0 (3.0-8.0) 4.0 (2.5-7.0) 6.5 (4.0-8.0) 0.488 HAQ score, 0-3 0.75 (0.38-1.25) 0.38 (0.25-0.81) 0.88 (0.63-1.38) PASI 1.7 (0.0-9.75) 2.0 (0.0-7.3) 35 1.2 (0.0-11.5) 0.940 DAS28-CRP 3.77 (3.02-4.58) 3.44 (2.65-3.94) 4.07 (3.28-4.93) 0.001 Disclosure Interests: Peter Benzin: None declared., Zara Rebecca Stisen: Marie Skougaard: Tanja Schjødt Jørgensen Speakers bureau: Received consulting fees and/or speaking AbbVie, Pfizer, Roche, Novartis, UCB, Biogen Eli Lilly, Consultant of: Rebekka L. Hansen: Lourdes M. Perez-Chada: Mette Mogensen: Joseph F. Merola investigator Merck, Bristol-Myers Squibb, Dermavant, Janssen, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, EMD Sorono, Avotres Leo Pharma., Lars Erik Kristensen consultancy Amgen, Gilead, BMS, MSD, Janssen pharmaceuticals., pharmaceuticals.